Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland.
J Nucl Med. 2010 Nov;51(11):1771-9. doi: 10.2967/jnumed.110.076695. Epub 2010 Oct 18.
A variety of radiolabeled somatostatin analogs have been developed for targeting of somatostatin receptor (sst)-positive tumors. Bicyclic somatostatin-based radiopeptides have not been studied yet. Hypothesizing that the introduction of conformational constraints may lead to receptor subtype selectivity or may help to delineate structural features determining pansomatostatin potency, we developed and evaluated first examples of this new class of potential radiotracers for imaging or therapy of neuroendocrine tumors.
The bicyclic peptides were synthesized by standard solid-phase peptide synthesis. DOTA was coupled to the resin-assembled peptide for labeling with (177)Lu and (68)Ga. Binding affinity and receptor subtype profile were determined using human ssts. Ca(2+) flux, internalization, and efflux were studied in human embryonic kidney (HEK)-sst(2) and HEK-sst(3) cell lines. Biodistribution and PET/CT studies were performed in corresponding nude mice models.
Some of the new analogs showed high affinity for sst(2) and sst(3) and moderate affinity for sst(1), sst(4), and sst(5), while exhibiting agonistic properties. The analog AM3, comprising an octreotide ring and a head-to-tail-coupled Arg-diaminobutyric acid(DOTA) cycle, showed the highest receptor affinity and agonist potency. (177)Lu-AM3 showed high and receptor-mediated uptake in vivo in sst(2) and sst(3) tumors with low background. Kidneys were the only other tissue accumulating radioactivity that could be reduced by a preinjection of lysine. PET/CT studies of (68)Ga-AM3 at 1 h after injection were characterized by clear localization of the tumor, visualization of the kidneys, and negligible background.
The high rigidity of these new bicyclic somatostatin-based radiopeptides led to agonistic ligands with good affinity for all 5 ssts. The pharmacokinetic data of (177)Lu/(68)Ga-AM3 make this peptide an excellent candidate as an imaging--and especially as a PET--radiotracer.
设计并评价新型双环 somatostatin 类似物作为神经内分泌肿瘤成像或治疗的潜在放射性示踪剂。
采用固相肽合成法合成双环肽。树脂偶联肽与 DOTA 连接,用于标记 (177)Lu 和 (68)Ga。采用人源 ssts 测定结合亲和力和受体亚型谱。在 HEK-sst(2)和 HEK-sst(3)细胞系中研究 Ca2+ 流、内化和外排。在相应的裸鼠模型中进行生物分布和 PET/CT 研究。
一些新型类似物对 sst(2)和 sst(3)显示出高亲和力和中等亲和力对 sst(1)、sst(4)和 sst(5),同时具有激动剂特性。包含 octreotide 环和 Arg-二氨基丁酸(DOTA)头尾偶联环的类似物 AM3 表现出最高的受体亲和力和激动剂效力。(177)Lu-AM3 在 sst(2)和 sst(3)肿瘤中具有高受体介导的摄取,背景低。肾脏是唯一积累放射性的其他组织,可通过预先注射赖氨酸减少。注射后 1 h 进行 (68)Ga-AM3 的 PET/CT 研究,肿瘤定位清晰,肾脏显影,背景可忽略不计。
这些新型双环 somatostatin 基放射性肽的高刚性导致了对所有 5 种 ssts 具有良好亲和力的激动性配体。(177)Lu/(68)Ga-AM3 的药代动力学数据使其成为一种优秀的成像候选物,尤其是作为 PET 放射性示踪剂。